Nektar Therapeutics

NKTR 
(NASDAQ) 
 
$ 31.98 <%= Resources.Global.txtDown %>
Updated 16/07/2019
Change % -1.57% Stock price decreasing
Change -0.51 Stock price decreasing
Volume 725,458
High $ 32.64
Low $ 31.90
Open $ 32.61
ISIN
Prev close $ 32.49
# of shares 174.31M
Market cap 5,574.33M USD
Intraday

Market closed
Nektar Therapeutics
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  31.98 -4.6% Stock price decreasing -9.1% Stock price decreasing 0.9% Stock price increasing -30.8% Stock price decreasing -33.2% Stock price decreasing
Powered by TradingView

Company profile

Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, chronic pain, hemophilia, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 July 2019 06:22:08
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190703.1 - EUROWEB3 - 2019-07-18 07:22:08 - 2019-07-18 06:22:08 - 1000 - Website: OKAY